Quick Take: Mydecine Innovations Group announced that it has submitted a formal application to list its common shares on the NASDAQ Stock Exchange. NASDAQ is the second-largest exchange by market capitalization worldwide and is home to many of the world’s best technology companies. Mydecine Innovations Group (MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), … [Read more...] about Mydecine Innovations Group Files Application to list to the NASDAQ
Press Releases
Psychedelics press releases from companies in the industry. Have something to announce? Publish your company news here!
Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US
Quick Take: Field Trip Health Ltd. announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021.Located in the Glenwood Park neighborhood, the Atlanta location is the first Field Trip Health center to open this year, following the opening of Toronto, New York, Los … [Read more...] about Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US
Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression
Quick Take: Champignon Brands Inc. Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario.This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment. Champignon … [Read more...] about Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression
PharmaTher Signs License Agreement for Patented Ketamine Treatment
Quick Take: PharmaTher has entered an agreement with the National Health Research Institutes of Taiwan to develop and commercialize a patented formulation of FDA-approved ketamine and betaine combination called KETABET. This new formulation is designed to treat mental health, neurological, and pain disorders. PharmaTher (PHRM) has entered an agreement with the National … [Read more...] about PharmaTher Signs License Agreement for Patented Ketamine Treatment
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Quick Take: Mydecine Innovations Group has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).The Horizons Psychedelic Stock Index ETF index, which was announced in December 2020 and includes 17 companies in the U.S. and Canada, is expected to start trading on Tuesday, January 26 under the ticker PSYK on the NEO exchange. Mydecine Innovations Group … [Read more...] about Mydecine Innovations Group Included in First-Ever Psychedelics ETF